Stock Scorecard



Stock Summary for Autolus Therapeutics plc (AUTL) - $6.24 as of 3/28/2024 3:32:39 PM EST

Total Score

9 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AUTL

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AUTL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AUTL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for AUTL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for AUTL

CORRECTION - AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee 3/28/2024 7:22:00 PM
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee 3/25/2024 12:10:00 PM
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee 3/25/2024 12:10:00 PM
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update 3/20/2024 10:15:00 AM
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views 3/18/2024 5:01:00 PM
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency ( MHRA ) certification for Nucleus commercial manufacturing site 3/12/2024 11:00:00 AM
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency ( MHRA ) certification for Nucleus commercial manufacturing site - Autolus Therapeutics ( NASDAQ:AUTL ) 3/12/2024 11:00:00 AM
Autolus Therapeutics announces publication in Blood Cancer Journal - Autolus Therapeutics ( NASDAQ:AUTL ) 3/11/2024 11:00:00 AM
Autolus Therapeutics announces publication in Nature Communications - Autolus Therapeutics ( NASDAQ:AUTL ) 2/22/2024 12:00:00 PM
Are Medical Stocks Lagging Ascendis Pharma ( ASND ) This Year? 2/15/2024 2:40:00 PM

Financial Details for AUTL

Company Overview

Ticker AUTL
Company Name Autolus Therapeutics plc
Country USA
Description Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 12/31/2023
Next Earnings Date 5/1/2024

Stock Price History

Last Day Price 6.24
Last Day Price Updated 3/28/2024 3:32:39 PM EST
Last Day Volume 412,935
Average Daily Volume 1,393,307
52-Week High 7.45
52-Week Low 1.61
Last Price to 52 Week Low 287.58%

Valuation Measures

Trailing PE N/A
Industry PE 66.35
Sector PE 60.76
5-Year Average PE -4.98
Free Cash Flow Ratio 6.93
Industry Free Cash Flow Ratio 17.10
Sector Free Cash Flow Ratio 31.04
Current Ratio Most Recent Quarter 6.15
Total Cash Per Share 0.90
Book Value Per Share Most Recent Quarter 0.64
Price to Book Ratio 14.72
Industry Price to Book Ratio 7.21
Sector Price to Book Ratio 21.66
Price to Sales Ratio Twelve Trailing Months 966.29
Industry Price to Sales Ratio Twelve Trailing Months 32.37
Sector Price to Sales Ratio Twelve Trailing Months 8.77

Share Statistics

Total Shares Outstanding 265,926,000
Market Capitalization 1,659,378,240
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -40.01%
Reported EPS 12 Trailing Months -1.20
Reported EPS Past Year -0.45
Reported EPS Prior Year -0.98
Net Income Twelve Trailing Months -208,395,000
Net Income Past Year -208,383,000
Net Income Prior Year -148,839,000
Quarterly Revenue Growth YOY -100.00%
5-Year Revenue Growth 113.88%

Balance Sheet

Total Cash Most Recent Quarter 239,566,000
Total Cash Past Year 239,566,000
Total Cash Prior Year 256,415,000
Net Cash Position Most Recent Quarter 239,566,000
Net Cash Position Past Year 239,566,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 111,474,000
Total Stockholder Equity Prior Year 180,518,000
Total Stockholder Equity Most Recent Quarter 111,474,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.03
MACD Signal -0.07
20-Day Bollinger Lower Band 4.19
20-Day Bollinger Middle Band 5.81
20-Day Bollinger Upper Band 7.43
Beta 1.89
RSI 57.20
50-Day SMA 3.87
200-Day SMA 5.65

System

Modified 3/27/2024 6:29:38 PM EST